| 摘要 |
Novel vasotocin derivatives having an inhibitory effect on uterine contractions, pharmaceutical compositions containing these derivatives, and the use thereof in the therapeutical treatment of excessive muscle contractions in the uterus and described. The derivatives differ from vasotocin in that the structure of the original hormone has been modified at positions 1, 2 and, optionally, 4 and/or 8. The vasotocin derivatives thus have the formula <IMAGE> wherein Mpa is a 3-mercaptopropionoyl residue (-S-CH2-CH2-CO-); A is the peptide residue of L- or D-tyrosine-O-ethyl ether (in other words, 4-ethoxy-L or D-phenyl alanine, i.e. L- or D-Tyr(Et)), or of a hydrophobic D-amino acid, such as D-tyrosine(D-Tyr) or D-tryptophane(D-Trp); Ile is the peptide residue of isoleucine; B is the peptide residue of glutamine (Gln), treonine (Thr) or valine (Val); Asn is the peptide residue of asparagin; Cys is the peptide residue of cysteine; Pro is the peptide residue of proline; C is the peptide residue of L- or D-arginine (Arg), ornithine (Orn) or citrullin (Cit); and Gly-NH2 is the peptide residue of glycine amide. |
